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Molecular and genetic studies have demonstrated that members of the Toll-like receptor (TLR) family are
critical innate immune receptors. TLRs are recognition receptors for a diverse group of microbial ligands
including bacteria, fungi, and viruses. This study demonstrates that distinct TLRs are responsible for the
recognition of Helicobacter lipopolysaccharide (LPS) versus intact Helicobacter bacteria. We show that the
cytokine-inducing activity of Helicobacter LPS was mediated by TLR4; i.e., TLR4-deficient macrophages were
unresponsive to Helicobacter pylori LPS. Surprisingly, the cytokine response to whole Helicobacter bacteria (H.
pylori, H. hepaticus, and H. felis) was mediated not by TLR4 but rather by TLR2. Studies of HEK293 trans-
fectants revealed that expression of human TLR2 was sufficient to confer responsiveness to intact Helicobacter
bacteria, but TLR4 transfection was not sufficient. Our studies further suggest that cag pathogenicity island
genes may modulate the TLR2 agonist activity ofH. pylori as cagA bacteria were more active on a per-cell basis
compared to cagA mutant bacteria for interleukin-8 (IL-8) cytokine secretion. Consistent with the transfection
studies, analysis of knockout mice demonstrated that TLR2 was required for the cytokine response to intact
Helicobacter bacteria. Macrophages from both wild-type and TLR4-deficient mice produced a robust cytokine
secretion response (IL-6 and MCP-1) when stimulated with intact Helicobacter bacteria. In contrast, macro-
phages from TLR2-deficient mice were profoundly unresponsive to intact Helicobacter stimulation, failing to
secrete cytokines even at high (100:1) bacterium-to-macrophage ratios. Our studies suggest that TLR2 may be
the dominant innate immune receptor for recognition of gastrointestinal Helicobacter species.
Helicobacter pylori is a gram-negative, spiral-shaped bacte-
rium that infects half of the world’s population (29). While
infection with H. pylori invariably leads to a chronic inflamma-
tory response (chronic active gastritis), most infected patients
remain asymptomatic, with only minimal inflammation (62).
However, a significant percentage of patients do progress to
more serious outcomes, which include peptic ulcer disease,
gastric lymphoma, and gastric cancer (12, 22, 42, 57). On the
basis of its strong link to gastric cancer, H. pylori has been
classified by the International Agency for Research on Cancer
(a branch of the World Health Organization) as a class I
carcinogen (29). In both animal models (40, 79) and human
studies (14, 15), progression of H. pylori disease from super-
ficial gastritis to gastric cancer appears to be related to the se-
verity of the host inflammatory response. The identification of
H. pylori components and host factors that contribute to the
inflammatory response may lead to important insights into the
mechanism of peptic ulcer disease and/or gastric malignancy.
Although H. pylori induces chronic mucosal inflammation to
some degree in all infected patients, the organism does not
appear to invade the gastric epithelium (reviewed in reference
27). Gastric epithelial cells and macrophages are considered to
be the main sources of proinflammatory cytokines and key
components of innate immunity. With respect to H. pylori, the
gastric epithelial cell layer is thought to represent the first line
of defense and the initial trigger for host innate and inflam-
matory responses (8, 19, 65). H. pylori has been shown to
activate intracellular signaling in gastric epithelial cells, leading
to transcriptional responses. Epithelial cells release a variety of
proinflammatory mediators including both cytokines and che-
mokines, leading to the subsequent attraction of monocytes/
macrophages. In addition, both epithelial cells and macro-
phages appear to recognize microbial pathogens by sampling
the environment with a family of receptors that discriminate
between pathogens and self, pattern recognition receptors
known as the Toll-like receptor (TLR) family (8, 19, 65).
Several animal models of Helicobacter-induced gastrointes-
tinal inflammation and gastric cancer have been developed (40,
79, 80). H. felis is a mouse pathogen, and infection of C57BL6
mice mimics many of the pathogenic changes commonly found
in humans infected with H. pylori (40, 80). H. pylori from
human isolates is not usually a mouse pathogen; however, a
mouse-adapted strain, H. pylori SS1, has proven very useful in
modeling gastric disease and cancer progression in mice (41,
75). H. hepaticus is an endogenous mouse pathogen. H. hepati-
cus infection produces a typhlocolitis in mice (16, 17). Re-
cently, H. hepaticus infection has been shown to lead to the
development of colon cancer in Rag-2-deficient mice (18). The
receptors involved in the inflammatory response to H. hepati-
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cus are largely unknown, although a prominent role for NF-B
has been demonstrated in studies by Erdman et al. (16).
In this study, we have investigated the role of TLRs in the
recognition of H. pylori, H. felis, and H. hepaticus. With normal
human monocytes and macrophages, transfected cell lines, and
genetically deficient animals, we demonstrate that TLR2 is an
important cytokine signaling receptor for H. pylori, H. felis, and
H. hepaticus. Further, we demonstrate that although the lipo-
polysaccharide (LPS) of H. pylori is recognized by TLR4, the
major TLR for intact Helicobacter bacteria is TLR2, not TLR4.
MATERIALS AND METHODS
Human cells and cell lines. Human embryonic kidney (HEK293) cells (Amer-
ican Type Culture Collection, Manassas, Va.) were grown in RPMI 1640 medium
or Dulbecco modified Eagle medium (Gibco BRL, Grand Island, N.Y.) supple-
mented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals,
Norcross, Ga.). HEK293 cells stably expressing human TLR2, TLR4, MD2,
and/or CD14 were engineered as previously described (38). Peripheral blood
mononuclear cells (PBMC) were isolated from normal human donors by Ficoll-
Hypaque gradient centrifugation (Lymphocyte Separation Medium; Mediatech,
Herndon, Va.). Monocytes were isolated by countercurrent centrifugal elutria-
tion of mononuclear leukocyte-enriched cell preparations from leukapheresis
donors. Macrophages were differentiated from blood monocytes by culturing the
cells in the presence of 1,000 U of macrophage colony-stimulating factor (R&D
Systems, Minneapolis, Minn.) per ml for 2 days and in culture medium (Dul-
becco modified Eagle medium plus 10% fetal bovine serum) alone for an addi-
tional 8 to 14 days (76).
PECs. Murine peritoneal exudate cells (PECs) were harvested from mice
injected intraperitoneally with 1 ml of 4% thioglycolate after 4 days by peritoneal
lavage with Ca2- and Mg2-free sterile saline. TLR2-deficient mice were the
gift of S. Akira (Osaka, Japan) (24). TLR4-deficient C57BL/10ScN mice were
obtained from the National Cancer Institute. C57BL/6, C57BL/6  129Sv F2
(B6129F2), and C57BL/10SnJ wild-type control mice were purchased from The
Jackson Laboratory (Bar Harbor, Maine).
Cells were cultured in 24-well culture dishes at densities of 105 to 106 cells per
well in 1 ml of medium. HEK293 cells at 105/ml, PBMC at 106/ml, monocytes and
macrophages at 105/ml, and PECs at 105 to 106/ml were used. Cells were stim-
ulated with LPS (1 to100 ng/ml), Pam3CSK4 (10 to100 ng/ml), or bacteria (103 to
109 CFU/ml). For analysis of cytokine secretion, culture supernatants were har-
vested 18 h after stimulation and cytokine levels were determined by enzyme-
linked immunosorbent assay (ELISA) (OptEIA; BD-Pharmingen). For analysis
of cytokine gene transcription, cells were stimulated with bacteria or medium
alone for 2 h. The cells were harvested and lysed, and RNA was prepared with
a commercial RNA extraction kit (RNeasy; QIAGEN, Valencia, Calif.). Total
mRNA (5 g per blot) was reverse transcribed, labeled with biotin, and hybrid-
ized to a Mouse Inflammatory Cytokine SuperArray in accordance with the manu-
facturer’s (SuperArray Inc., Frederick, Md.) instructions. Chemiluminescent images
on film were transilluminated, scanned, and analyzed with GEArray software.
LPS preparations. LPS from Escherichia coli serotype O111:B4 was purchased
from Sigma (St. Louis, Mo.). Phenol extraction of the LPS to remove contami-
nating lipopeptides was performed as described elsewhere (26). The following
clinical isolates of H. pylori were also used as sources of LPS: AM1, isolated from
a patient with chronic gastritis; AM2 and AM3, from patients with superficial
gastritis; AM4, from a patient with chronic atrophic gastritis; AM5, from a
patient with intestinal metaplasia; and AM6, from a patient with gastric adeno-
carcinoma. Similarly, LPS was obtained from clinical isolates of E. coli and
Salmonella enterica (55).
Bacterial biomass was obtained by growth of H. pylori strains on blood agar
under microaerobic conditions (54). H. pylori LPS was obtained from this bio-
mass by phenol-water extraction and subsequent enzymatic purification with
RNase A, DNase II, and proteinase K, as well as by ultracentrifugation as
described previously (55). The H. pylori LPS obtained was essentially free of
proteins (0.1%) and nucleic acids (0.1%) and had an electrophoretic profile
similar to that reported previously for the high-molecular-mass LPS of other
H. pylori strains (54). Moreover, in the Limulus amebocyte lysate assay and for
induction of tumor necrosis factor alpha, the LPS exhibited bioactivities identical
to those reported previously (63). High-molecular-mass LPS was produced by
these strains when they were grown either on solid medium or in liquid culture.
Importantly, the H. pylori LPS used in these studies was free of contaminating
peptidoglycan as determined in biochemical assays (A. P. Moran, unpublished
results), and furthermore, the bioactivities of these preparations was unaffected
by treatment with lysozyme, which removes trace peptidoglycan contamination
(data not shown).
Helicobacter strains. H. pylori SS1, H. pylori ATCC 43504 (cagA vacA), H.
pylori Astra 244 (cagA vacA), H. hepaticus (ATCC 51449), and H. felis (ATCC
49179) were grown on tryptic soy broth-blood agar (Becton Dickinson, Cock-
eysville, Md.), harvested, and washed, and the optical density at 600 nm and CFU
counts were determined (28). Bacteria were stored in aliquots at 70°C. On the
day of assay, the bacteria were washed in sterile saline, recovery was checked by
determining the optical density at 600 nm, and the bacteria were resuspended to
109/ml in sterile saline. Serial dilutions of the bacteria were prepared in culture
medium immediately prior to addition to the cell cultures. Cells and bacteria
were incubated together in tissue culture medium for 18 h at 37°C, and culture
supernatants were harvested for cytokine analysis. (Experiments with bacteria
grown in liquid culture showed the same results. Data are representative of at
least three independent experiments.)
RESULTS
H. pylori activates the innate immune response in human
cells. Normal human peripheral blood cells incubated with H.
pylori SS1 bacteria secreted inflammatory cytokines, including
interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor
alpha (Fig. 1). Cytokines were produced in a dose-dependent
manner by PBMC upon incubation with H. pylori SS1 bacteria
(Fig. 1A). Purified human monocytes and monocyte-derived
human macrophages exhibited similar dose-dependent cytokine
responses to H. pylori bacteria (Fig. 1B and C). Optimal cytokine
FIG. 1. Human monocytes and macrophages challenged with whole
H. pylori bacteria secrete inflammatory cytokines. Human PBMC (A),
purified monocytes (B), or monocyte-derived macrophages (C) were
stimulated with various numbers of H. pylori SS1 bacteria or medium
alone. Culture supernatants were harvested following an 18-h incuba-
tion, and IL-6, IL-8, and IL-1 levels were determined by cytokine-
specific ELISA.
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secretion was observed at a dose of approximately 108 H. pylori
SS1 CFU/105 monocytes (Fig. 1B) or macrophages (Fig. 1C).
Human monocytes and macrophages express innate immune
receptors, including TLR2, TLR4, and the pattern recognition
receptor CD14. These receptors participate in the inflammatory
response to a variety of bacteria and bacterial products, including
LPS from gram-negative bacteria, peptidoglycan from gram-pos-
itive bacteria, and yeast zymosan. Therefore, we determined if
these receptors are also important for the response to H. pylori.
Human TLR2 expression is sufficient to confer responsive-
ness to H. pylori bacteria. We investigated the role of TLRs in
the response to H. pylori in gain-of-function studies with stably
transfected HEK293 cells. Transfection of HEK293 cells with
human TLR4 confers responsiveness to the TLR4 ligand
E. coli LPS (10, 38). Likewise, transfection with human TLR2
confers responsiveness to TLR2 ligands, such as yeast zymosan
and S.aureus peptidoglycan (38, 44). CD14 expression en-
hances the response of HEK293 cells to both TLR2 and TLR4
ligands (10, 38, 44).
We examined the response of HEK293 cells stably trans-
fected with CD14 alone or in combination with TLR2 or TLR4
to H. pylori. Intact H. pylori bacteria induced IL-8 secretion
from cells expressing TLR2 and CD14 but not from cells ex-
pressing TLR4 and CD14 or CD14 alone (Fig. 2A). The IL-8
response of TLR2- and CD14-expressing cells to H. pylori SS1
bacteria was dose dependent (Fig. 2A and B). These results
suggested that although H. pylori is a gram-negative bacterium,
the cytokine secretion response to whole H. pylori bacteria
occurs by TLR2, rather than TLR4, receptor stimulation.
cagA H. pylori stimulation of TLR2-expressing cells. Stud-
ies from several laboratories have shown that a set of H. pylori
genes in the cag pathogenicity island influences the cytokine-
stimulating activity of H. pylori. To address the role of the cag
region genes in the TLR2 agonist activity of intact H. pylori
bacteria, cagA and cagA mutant H. pylori bacteria were used
to stimulate TLR2- and CD14-expressing HEK293 cells (Fig.
2B). Both strains of bacteria stimulated IL-8 secretion from the
TLR2- and CD14-expressing cells, indicating that cagA is not
required for a TLR2-mediated cytokine response. Neverthe-
less, cagA bacteria were 2 logs more potent stimulators of IL-
8 secretion than cagA mutant bacteria and the response to cagA
bacteria was dependent on TLR2 expression, suggesting that
cagA (or genes associated with cagA in the cag pathogenicity
island) augments the TLR2 response either directly or by regu-
lating the expression of other TLR2 target molecules on H. pylori.
H. hepaticus bacteria activate cytokine secretion via TLR2.
Similar to the response seen with H. pylori, whole H. hepaticus
bacteria stimulated IL-8 secretion (Fig. 3) from HEK293 cells
FIG. 2. Whole H. pylori bacteria are potent stimulators of HEK293
cells expressing TLR2 but not TLR4. (A) HEK293 cell clones stably
expressing CD14, TLR2 and CD14, or TLR4 and CD14 were stimu-
lated with H. pylori SS1 bacteria or medium alone. (B) TLR2- and
CD14-expressing HEK293 cell clones were stimulated with various
numbers of cagA or cagA mutant H. pylori bacteria or medium alone.
Culture supernatants were harvested after an 18-h incubation, and
IL-8 levels were determined by ELISA.
FIG. 3. Whole H. hepaticus bacteria activate TLR2-expressing but
not TLR4-expressing HEK cells. HEK293 clones stably expressing
TLR2 and CD14, TLR4 and MD2, or CD14 alone (control) were stim-
ulated with H. hepaticus bacteria (upper panel), Pam3CSK4 (TLR2
ligand, middle panel), E. coli LPS (TLR4 ligand, lower panel), or
medium alone. Culture supernatants were harvested after an 18-h
incubation, and IL-8 levels were determined by ELISA.
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transfected with human TLR2. The response was dose depen-
dent, and IL-8 secretion was detectable at bacterium-to-cell
ratios as low as 0.5:1 (Fig. 3). In contrast, neither H. hepaticus
nor H. pylori bacteria activated TLR4 (and MD2)-expressing
HEK293 cells, although the TLR4-expressing HEK293 cells
responded to an LPS challenge (Fig. 2 and 3).
H. pylori bacteria activate inflammatory cytokine gene ex-
pression and secretion from murine macrophages. Like hu-
man monocytes and macrophages, mouse peritoneal macro-
phages incubated with whole H. pylori bacteria exhibited a
robust inflammatory cytokine response (Fig. 4). Gene array
analysis of peritoneal macrophages demonstrated upregulation
of a large number of inflammatory cytokine and chemokine
genes within 2 h of stimulation of the macrophages with whole
H. pylori bacteria (Fig. 4A). This increase in gene expression
was reflected at the protein level; H. pylori induced a dose-
dependent increase in the synthesis and secretion of inflam-
matory cytokines, including IL-6 and MCP-1, from mouse mac-
rophages (Fig. 4B).
TLR2 knockout macrophages are unresponsive to H. pylori
bacteria, while TLR4-deficient macrophages respond nor-
mally. The gain-of-function studies of transfected cell lines
indicated that TLR2 plays an important role in the response to
whole H. pylori bacteria. We next determined if the targeted
deletion of TLR2 in knockout mice would affect the inflam-
matory response to H. pylori bacteria. Peritoneal macrophages
from wild-type and TLR2/ mice were cultured with H. pylori
bacteria, and the release of cytokines was measured. Wild-type
macrophages secreted IL-6 in response to H. pylori bacteria,
while TLR2/ macrophages failed to respond to H. pylori
(Fig. 4B), even at very high doses of bacteria (109 CFU/106
macrophages). Control cultures demonstrated a robust cyto-
kine response of wild-type and TLR2/ macrophages to E.
coli LPS (Fig. 4C) and to IL-1 (data not shown). As expected,
TLR2/ macrophages were unresponsive when challenged
with the TLR2 ligands (i.e., zymosan and peptidoglycan) (11,
70; data not shown), whereas TLR4-deficient macrophages
were unresponsive to LPS (Fig. 4C).
In a similar experiment, we compared wild-type and TLR2-
and TLR4-deficient macrophage responses to H. pylori SS1
and H. felis (Fig. 5). We wanted to determine whether (i) the
failure of TLR2/ mice to respond to H. pylori SS1 was
peculiar to this species of Helicobacter or whether responses to
other gastric Helicobacter species were also deficient in these
animals and (ii) whether TLR4 is necessary for the cytokine
response to Helicobacter bacteria. These studies demonstrate
that TLR2/ macrophages failed to respond to either Heli-
cobacter species (Fig. 5A and B). In contrast, TLR4-deficient
mice had an enhanced response to both Helicobacter species
compared to the response of control (wild-type) animals (Fig.
5A and B). (The basis for the hyperresponsiveness of TLR4-
deficient macrophages to Helicobacter bacteria is not clear, but
it may reflect higher levels of TLR2 expression on these mac-
rophages or increased availability of intracellular adaptor or
signaling components in the absence of TLR4 expression.)
Thus, TLR2 but not TLR4 was necessary and sufficient for the
cytokine response to intact Helicobacter bacteria.
FIG. 4. Murine macrophages are activated by whole H. pylori SS1
bacteria in a TLR2-dependent manner. (A) Wild-type mouse perito-
neal exudate macrophages were stimulated with medium (left panel)
or H. pylori SS1 bacteria (right panel). Following a 2-h incubation,
RNA was extracted, labeled, and hybridized to a mouse SuperArray
blot. The positions of inflammatory cytokine and cytokine receptor
spots are indicated. (Bottom two rows) Negative controls included
blanks and pUC18. Positive controls included the gene for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and housekeeping genes
(those for cyclophilin A and actin). (B) Wild-type and TLR2 knockout
(KO) mouse peritoneal exudate macrophages were stimulated with
medium (None) or H. pylori SS1 bacteria (107 to 109 per well). Super-
natants were harvested 18 h later, and IL-6 levels were determined by
ELISA. (C) Wild-type, TLR2 knockout, or TLR4-deficient (def) ScN
mouse peritoneal exudate macrophages were stimulated with medium
alone or E. coli LPS (TLR4 ligand). Supernatants were harvested 18 h
later, and IL-6 levels were determined by ELISA.
FIG. 5. H. pylori SS1 and H. felis both activate murine macrophages
in a TLR2-dependent, TLR4-independent manner. Wild-type, TLR2-
knockout (KO), and TLR4-deficient (def) mouse peritoneal exudate
macrophages were stimulated with medium alone or with H. pylori SS1
(left panel) or H. felis (right panel) bacteria. Supernatants were har-
vested 18 h later, and IL-6 levels were determined by ELISA.
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H. pylori LPS stimulates cytokine secretion via TLR4. We
next determined if the LPS component of H. pylori could stim-
ulate an inflammatory response similar to that seen with whole
bacteria. LPS from gram-negative bacteria, such as E. coli,
stimulates the innate immune response through TLR4. This
response is independent of TLR2 expression (23, 26, 77). In
contrast to E. coli, the innate immune response to H. pylori was
dependent on TLR2 but not TLR4. To determine if differences
in the structure of the LPS of E. coli compared to that of H.
pylori LPS could account for differences in TLR activation, we
compared the E. coli and H. pylori LPSs as stimulants of wild-
type, TLR2/, and TLR4-deficient macrophages. The LPSs
of both E. coli and H. pylori activated macrophages in a dose-
dependent (Fig. 6) and TLR4-dependent (Fig. 7) manner.
Thus, H. pylori LPS preparations triggered cytokine secretion
from wild-type and TLR2/ macrophages, as well as from
TLR4-transfected HEK293 cells (Fig. 7A, B, and D). In con-
trast, H. pylori LPS failed to activate TLR4/ macrophages or
control HEK293 cells (Fig. 7C and data not shown).
As noted in other studies, LPS prepared from clinical iso-
lates of H. pylori varies substantially in its cytokine-stimulating
activity (5, 31, 35). We observed that LPS from isolates AM5
and AM6 induced a robust IL-6 cytokine response (Fig. 6).
LPS from isolates AM1, -2, -3, and -4 induced lesser levels of
IL-6 (Fig. 6). These differences in activity may reflect variations
in the degree of acylation and/or phosphorylation of the LPS in
these different clinical isolates (Moran, unpublished). Differ-
ences in the core and O chains of the LPS from the individual
isolates are also observed that could perhaps modulate the
cytokine-inducing activity of the lipid A component of LPS
(Moran, unpublished).
Overall, the H. pylori LPS preparations were 1 to 2 logs less
stimulatory than either E. coli or Salmonella LPS similarly
prepared from clinical isolates (Fig. 6). Nevertheless, all of the
H. pylori LPS preparations tested that were active in assays
with wild-type cells (i.e., AM1, AM4, AM5, and AM6) dis-
played the same TLR4-dependent, TLR2-independent pattern
of response (Fig. 7). Similarly, differences in the structure of
the LPS derived from H. pylori compared to that of the LPS
from E. coli cannot account for the TLR2 dependence of the
response to intact H. pylori bacteria (53, 56). Taken together,
our studies suggest that TLR4 expression was both necessary
and sufficient for a robust cytokine secretion response to H. py-
lori LPS, whereas TLR2 expression was required for respon-
siveness to intact Helicobacter bacteria.
Intact E. coli bacteria stimulate both TLR2- and TLR4-
expressing cells. We directly compared the TLR2 and TLR4
dependence of cytokine secretion induced by intact E. coli and
H. pylori bacteria (Fig. 8). E. coli bacteria induced IL-6 secre-
tion from both wild-type and TLR2 knockout peritoneal mac-
rophages but only weakly activated TLR4 knockout cells (Fig.
8). In contrast, H. pylori bacteria activated wild-type and TLR4
knockout cells but not TLR2 knockout cells. H. pylori bacteria
were weak inducers of cytokine secretion compared to E. coli
bacteria on a per-cell basis (Fig. 8 and data not shown). Al-
though the response of peritoneal macrophages to E. coli bac-
teria was largely TLR4 dependent, both TLR2- and TLR4-
expressing HEK293 cells secreted cytokines in response to
E. coli bacteria, indicating that both receptors potentially con-
tributed to the response to intact E. coli (Fig. 8). In contrast,
H. pylori bacteria activated TLR2-expressing, but not TLR4-
expressing, HEK293 cells (Fig. 8). Thus, intact H. pylori acti-
vated TLR2, while intact E. coli activated both TLR2 and
TLR4, although TLR4 was the predominant activating recep-
tor for E. coli on normal macrophages.
DISCUSSION
TLRs are transmembrane proteins that function as pattern
recognition receptors for the detection and response to micro-
bial ligands (reviewed in references 30, 32, and 37). To date, 10
TLRs have been identified in humans and natural or synthetic
ligands for at least 9 TLRs have been identified (9, 30, 32, 33,
37, 52, 67). The extracellular regions of TLRs are diverse but
contain variable numbers of leucine-rich repeat regions and
conserved cysteine domains that are thought to contribute to
receptor structure and function. All of the TLRs have a signa-
ture intracellular signaling motif in common with the IL-1
receptor, called the TIR (Toll–IL-1–R) domain (6, 9, 52, 67).
Activation of TLRs results in the recruitment of adaptor pro-
teins, including MyD88 and Mal/TIRAP, to the TIR domain.
A series of phosphorylation-recruitment-activation events
leads to the activation and translocation of NF-B to the nu-
cleus and the transcription of inflammatory cytokine genes (1,
30, 50, 51, 59).
Ligands recognized by TLRs can be found among many
genera of bacteria, viruses, and fungi (3, 7, 44, 49, 77, 78, 82).
These include LPS from gram-negative bacteria (TLR4 li-
gand), peptidoglycan and lipoteichoic acid from gram-positive
bacteria (TLR2 ligands), and zymosan from yeast (TLR2 li-
gand). Recent data also indicate that TLRs are important in
the innate immune response to bacterial DNA (TLR9 [24])
and viral RNA (TLR3 [2]), as well as intact bacteria and vi-
ruses (TLR2 and TLR4 [11, 39]).
Our data demonstrate that TLR2 is a critical receptor for
the recognition of intact H. pylori bacteria. This is remarkable
since most gram-negative bacteria preferentially activate TLR4
FIG. 6. Dose-dependent activation of cytokine secretion and com-
parison of LPS preparations purified from E. coli with those from
clinical isolates of H. pylori. Wild-type peritoneal exudate macrophages
were stimulated with medium alone or with various doses of LPS
isolated from E. coli, S. enterica, or clinical isolates of H. pylori (des-
ignated AM1 to -6). Following an 18-h incubation, supernatants were
harvested and IL-6 levels were determined by ELISA.
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by the interaction of the potent TLR4 ligand with LPS in their
outer membrane (reviewed in reference 43). Although the LPS
produced by most gram-negative bacteria activates via TLR4, a
reported notable exception is the LPS of Porphyromonas gin-
givalis, which is a ligand for TLR2 but not TLR4 (48). Our
studies of the LPS derived from different H. pylori isolates
indicate that H. pylori LPS is a TLR4 ligand similar to the LPS
of other gram-negative strains, such as E. coli and Salmonella
spp. Thus, the TLR2 dependence of the response to intact H. py-
lori cannot be explained by the expression of an unusual LPS.
Consistent with our finding, the previously published studies
of Kawahara et al. (34, 36) demonstrated that the response to
H. pylori LPS occurs via TLR4 in guinea pig gastric pit cells. In
contrast, Smith et al. (74) recently reported that H. pylori LPS
activated via TLR2, not TLR4. The reason for the discrepancy
between their study and the present report (as well as the
studies of Kawahara et al. [34, 36]) is not clear. However, by
using the same experimental approach as Smith et al. (74), i.e.,
transfected HEK293 cells, we have found that H. pylori LPS
from clinical isolates signals preferentially via TLR4. Further-
more, with knockout macrophages we found that H. pylori LPS
does not elicit a cytokine response from TLR4-deficient mac-
rophages; the response of TLR4-deficient macrophage to TLR2
ligands such as zymosan, peptidoglycan, and lipopeptides was
indistinguishable from the response of wild-type macrophages,
indicating that the TLR4-deficient macrophages had an intact
TLR2-signaling capacity. One possible explanation for the dis-
crepancy between our results (as well as the studies of Kawa-
hara et al. [36]) and those of Smith et al. (74) is the strain of
bacteria from which the LPS was isolated. Smith et al. (74)
used only one H. pylori strain (26695), a heavily passaged
laboratory strain, to prepare their LPS. In the present studies,
we used a number of clinical isolates of H. pylori for LPS
purification. It has been previously established that clinical
isolates and laboratory strains of H. pylori have very different
LPS molecules and that passage of H. pylori and culture con-
ditions can induce variation in the LPS structures expressed
(54, 55, 71).
It is also noteworthy that the dosages of H. pylori LPS used
for cytokine stimulation in the present study were much lower
than the dosages at which Smith et al. detect TLR2 agonist
activity in their H. pylori LPS (i.e., nanograms per milliliter
compared to micrograms per milliliter) (74). A potential dif-
ference between the H. pylori LPS studied by Smith et al. (74)
and the LPS preparations in the present study may be the level
of trace contaminants such as peptidoglycan or lipopeptides,
both potent TLR2 agonists (26, 38, 72).
Despite the capacity of H. pylori LPS to activate via TLR4,
the response to intact H. pylori bacteria was dependent on
TLR2, and not TLR4, expression. This suggests that a non-LPS
component of the bacterium is the major cytokine-activating
molecule. It also raises the question of why it is difficult to
detect a TLR4-dependent response to H. pylori LPS on the
intact bacterium. One reason may be that H. pylori LPS is only
weakly active as a cytokine inducer, even under ideal condi-
tions, i.e., when it is added in a purified form to cultured cells.
We and others (Fig. 7 and references 5, 58, 63, and 64) have
noted that H. pylori LPS is 100- to 10,000-fold less active than
the LPS of other gram-negative bacteria, such as E. coli. It is
estimated that E. coli bacteria yield 10 ng of LPS per 106 CFU
FIG. 7. LPS preparations from clinical isolates of H. pylori are
TLR4 ligands. Wild-type peritoneal exudate macrophages (A), TLR2
knockout macrophages (B), TLR4-deficient macrophages (C), or TLR4-
expressing HEK293 cells (D) were stimulated with medium alone, LPS
isolated from E. coli O11B4, or LPS from clinical isolates of H. pylori.
All LPS stimulations were done with protein-free LPS re-extracted
with 10 ng of phenol/ml. H. pylori LPS was prepared from six different
clinical isolates (designated AM1 to -6) as detailed in Materials and
Methods. Following an 18-h incubation, supernatants were harvested
and IL-6 (macrophages) or IL-8 (TLR4-expressing HEK293 cells) lev-
els were determined by ELISA.
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of bacteria (66). Given its weak intrinsic activity (1,000-fold
lower than the activity of E. coli LPS), a response to H. pylori
LPS on intact bacteria would be difficult to detect with chal-
lenge doses of less than 108 to 109 CFU even if all of the H. py-
lori LPS were exposed and accessible for interaction with TLR4.
Although the LPS of H. pylori is apparently not the major
determinant of the response to intact H. pylori bacteria, the
LPS-TLR4 interaction may, nevertheless, play a role in disease
pathogenesis. This may be particularly important in the stom-
ach, where we and others have failed to detect TLR2 expres-
sion (60; unpublished observations). In contrast, TLR4 has
been detected on gastric pit cells, where it may sample the
stomach environment for pathogens (34). In the absence of
TLR2, the interaction of H. pylori LPS with TLR4 may be
critical to the early detection of H. pylori infection or coloni-
zation. Several previous studies have suggested that H. pylori
may activate the innate immune response through interactions
between its LPS and TLR4. Initial work by Sakagami et al. (68)
demonstrated that C3H/He mice (with an intact TLR4-encod-
ing gene) show severe atrophic gastritis in response to H. felis
infection, whereas C3H/HeJ mice (which have a mutated
TLR4-encoding gene and are LPS nonresponders) show heavy
colonization but minimal atrophic gastritis with a much re-
duced macrophage infiltration of the lamina propria. Recently,
Panthel et al. (61) showed that, in short-term colonization
studies, TLR2 knockout mice had reduced colonization com-
pared to C57BL/6J mice, but the degree of gastric inflamma-
tion was not reported. In addition, strain differences play an
important role in colonization, as C57BL/6 mice are reported
to have lower levels of colonization than either C3H/HeN or
C3H/HeJ mice (46). The importance of TLR4 in the H. pylori
response has been supported by work by another group that
has reported that guinea pig gastric pit cells express TLR4 and
show significant responses to H. pylori LPS (34, 36). Another
group has suggested that H. pylori NF-B activation in macro-
phages also involves TLR4 and CD14 (45).
Nevertheless, H. pylori LPS has been shown to be a weak
inducer of TLR4 activation with a potency that is 1,000- to
10,000-fold less than that of LPS from E. coli or S. enterica (5,
58, 63, 64). The lower bioactivity of H. pylori LPS compared to
that of E. coli LPS may reflect a lower interaction with TLR4
and/or MD2. The biochemical basis of the lower activity of
H. pylori LPS compared to that of E. coli LPS is the under-
phosphorylation of lipid A, as well as the presence of longer-
chain fatty acids than normally encountered with E. coli LPS
(53, 56). In addition, H. pylori LPS generally contains only four
fatty acids (56) rather than the six-fatty-acid architecture seen
in E. coli and other bioactive LPS molecules (53). Given its
relatively weak bioactivity, H. pylori LPS may not contribute to
the overall profile of bacterial stimulation or signaling seen
with intact H. pylori bacteria. Furthermore, it has also been
shown that H. pylori can activate cells by an LPS-independent
and TLR4-independent mechanism (4, 47). The importance of
the latter pathway relative to the LPS-dependent pathway in
macrophages has not been examined.
Our studies reveal a role for genes in the cag pathogenicity
island. In humans the induction of cytokine gene expression in
infected stomach tissue has been linked to the level of coloni-
zation with cagA H. pylori bacteria (73, 81). cagA H. pylori
bacteria were more potent activators of TLR2-expressing cells
than cagA mutant H. pylori, suggesting that cagA or other
associated cag pathogenicity island genes may themselves stim-
ulate cytokine secretion by activating TLR2 and CD14 recep-
tors. Alternatively, cag pathogenicity island-encoded genes
may regulate the expression levels of H. pylori components that
signal through TLR2 receptors. (Although cagA is a useful
marker for the cag pathogenicity island, cagA strains of H. py-
lori SS1 may have an incomplete cag region [13, 69].) In pre-
vious studies (reviewed in 21), cagA has been linked to IL-8
secretion from epithelial cells and is proposed to involve the
translocation of the CagA protein into epithelial cells and its
subsequent intracellular phosphorylation and activation of IL-
8-encoding gene expression (20, 25). Our studies suggest that
cagA-induced IL-8 secretion from transfected HEK cells is a
TLR2-dependent process, since HEK cells lacking TLR2 failed
to secrete IL-8 when challenged with cagA or cagA mutant
H. pylori bacteria. Nevertheless, cagA expression was not re-
quired for TLR2-induced cytokine secretion, since cagA mu-
tant strains of H. pylori, as well as H. felis and H. hepaticus,
which do not express cagA, all induced cytokine secretion via
TLR2.
In conclusion, our studies demonstrate that TLR2 is both
necessary and sufficient for responses to whole bacteria of
several Helicobacter species. A major, nonredundant role for
FIG. 8. E. coli bacteria activate cytokine secretion via both TLR2 and TLR4. Wild-type (WT), TLR2 knockout (KO), and TLR4 knockout
mouse peritoneal exudate macrophages were stimulated with E. coli or H. pylori bacteria (2.5  105 CFU/well, left panel). Supernatants were
harvested 18 h later, and IL-6 levels were determined by ELISA. (IL-6 levels were less than 200 pg/ml in medium controls.) HEK293 cells
transfected with TLR2 or TLR4 were stimulated with E. coli or H. pylori bacteria (106 CFU/well, right panel). Supernatants were harvested 18 h
later, and IL-8 levels were determined by ELISA. (IL-8 levels in medium controls were less than 200 pg/ml in HEK and HEK-TLR2 cells and
350 pg/ml in HEK-TLR4 cells.)
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TLR2 in the recognition of intact Helicobacter bacteria was
seen both with cell lines stably transfected with TLRs and with
normal cells from wild-type, TLR2 knockout, and TLR4
knockout animals. Moreover, TLR4 was neither necessary nor
sufficient for responses to intact Helicobacter bacteria. In con-
trast to the TLR2-dependent response to intact Helicobacter
bacteria, LPS as a pure lipid product extracted from the outer
membrane of Helicobacter bacteria and depleted of lipopro-
teins and glycan cell wall components was a ligand for TLR4
but its activity was variable. We demonstrated this with both
knockout animals and transfected cell lines. Thus, TLR4 (but
not TLR2) was both necessary and sufficient for response to
the isolated bacterial lipid, while TLR2 was required for re-
sponse to intact Helicobacter bacteria. (Control cultures dem-
onstrated that intact E. coli bacteria activated cytokine secre-
tion via both TLR2 and TLR4 and that TLR4 was the
dominant receptor on macrophages, consistent with the potent
agonist activity of E. coli LPS.)
We hypothesize that, upon initial infection in the stomach,
intact H. pylori bacteria may be weakly recognized by interac-
tion of its LPS with TLR4. However, a substantial inflamma-
tory cytokine response to H. pylori may only develop after the
recruitment and accumulation of TLR2-expressing cells, such
as infiltrating blood leukocytes (polymorphonuclear granulo-
cytes and monocytes) in the stomach (38). Thus, H. pylori may
escape detection and elimination by the immune system be-
cause it colonizes a TLR2-deficient environment (i.e., the
stomach) and at the same time expresses an LPS with very
weak TLR4 agonist activity.
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